Cyclophosphamide
Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 89/ 100
Competitive context
29 Active assets in the Advanced Solid Tumours cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ceralasertib AstraZeneca | Phase 2 | BB |
Epirubicin EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Phase 2 | B |
Senaparib Impact Therapeutics, Inc. | Phase 1/2 | B |
Pembrolizumab EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Phase 2 | B |
Durvalumab AstraZeneca | Phase 1/2 | B |
View all 50 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →